MT1013 for secondary hyperparathyroidism in dialysis patients
Part of Hormones & metabolism clinical trials.
This study tests a new injectable medicine called MT1013 for people with secondary hyperparathyroidism who are on regular kidney dialysis. It aims to see if MT1013 can help control high parathyroid hormone levels safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are on maintenance hemodialysis at least 3 times a week (or 5 times over 2 weeks) for at least 3 months.
- You are 18 years old or older.
- You have been diagnosed with secondary hyperparathyroidism (SHPT).
- Your dialysis fluid calcium level is at least 1.25 mmol/L (your dialysis center will confirm this).
- You are not taking certain other SHPT medicines (like Sensipar or Parsabiv) during the study, and you haven't used a RANKL inhibitor (like Prolia) in the last 6 months.
- You have not had parathyroid surgery in the last 6 months and do not plan to have it during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called MT1013 for people with secondary hyperparathyroidism who are on dialysis. It may help control high parathyroid hormone levels when current treatments are not enough.
This trial studies etelcalcetide in children who have chronic kidney disease and too much parathyroid hormone while on hemodialysis. It aims to safely lower the hormone levels and help manage related bone/mineral problems.
This Phase 3 trial tests etelcalcetide to lower a hormone called parathyroid hormone (PTH) in children who have kidney disease and secondary hyperparathyroidism while on hemodialysis. It may help control bone/mineral problems, but the study also checks heart rhythm safety and medication stability.
This study tests a new extended-release capsule (CTAP101) for children aged 8 to under 18 with moderate to severe chronic kidney disease (CKD). The goal is to see how the drug works in the body, if it's safe, and if it can help control mineral and hormone levels that are often out of balance in CKD.
This study tests whether a drug called Etelcalcetide can help preserve the activity of vitamin K-dependent proteins in people on hemodialysis who have severe overactive parathyroid glands. It may help reduce calcium buildup in blood vessels.
This study tests a new drug called XH-02 for hypoparathyroidism—a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels. If you haven't improved with standard calcium and vitamin D treatments, this trial may help.
Hear when a new Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.